Developer docs
API playgroundTry for free, no card

Search company profiles

InVivo Biosystems

Full company profile

uuid0000v8t

Namestring
InVivo Biosystems
Legal namestring
InVivo Biosystems
Company typeenum
Private
Founded yearint
2011
Descriptiontext

InVivo Biosystems is a privately held contract research organization (CRO) founded in 2011 and headquartered in Eugene, Oregon, that provides genome editing and preclinical research services using whole-organism models—primarily zebrafish and C. elegans. The company targets pharmaceutical and biotechnology companies, academic research institutions, and nutraceutical firms, positioning its services as faster, more cost-effective alternatives to traditional rodent-based preclinical workflows. Since inception, InVivo Biosystems has served 400+ clients, delivered 600+ studies, and produced 3,000+ C. elegans transgenic lines, with stated outcomes of 79% treatment correlation to traditional PDX oncology benchmarks and up to 98% reduction in validation study timelines.

The company's core offering is the RapidGen™ Platform, an AI-augmented in vivo discovery system that integrates conserved biology models, advanced genetics, multi-omics readouts, and computer-vision-based behavioral phenotyping to produce decision-ready data packages. Proprietary technologies include MIC-Drop™ (a multiplexed CRISPR platform exclusively licensed from the University of Utah, enabling simultaneous gene editing in F0 generation with non-linear labor scaling), the ZTX® Oncology Platform (zebrafish tumor xenograft for cancer drug efficacy testing, co-developed with BioReperia), and the FishCam Smart Rack (an AI-powered continuous zebrafish colony monitoring system funded through NIH SBIR grants). The intellectual property portfolio includes 10+ issued patents covering gene editing methods, whole-organism phenotyping, and automation.

InVivo Biosystems operates a fee-for-service revenue model with project-based contracts covering CRISPR gene editing (knock-in, knockout, transgenic services), preclinical compound efficacy and toxicity testing, disease modeling across neurological and metabolic indications, and genomic services including strain validation and storage. Pricing is unit-based, with gene editing projects ranging from $440 (Inject Express) to $3,812+ (Full Build CRISPR knock-in), with 50/50 milestone payment structures. The company pursues a consultative, partnership-driven sales motion targeting enterprise clients through direct engagement. Cumulative funding across equity rounds and grants totals approximately $12.8 million, including a $3M seed round led by Rogue Venture Partners in January 2024 and $2.8M in NIH grant funding, supplemented by Phase II SBIR support for FishCam development.

Short descriptiontext

InVivo Biosystems is an Eugene, Oregon-based contract research organization providing CRISPR gene editing and preclinical research services using zebrafish and C. elegans whole-organism models for pharmaceutical, biotech, academic, and nutraceutical clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEugene, United States
HQ citystring
Eugene
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical research services, CRISPR gene editing, zebrafish disease models, contract research organization, in vivo drug discovery
Industry1 code
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Fee-for-service preclinical research services including compound efficacy testing, toxicity testing, disease modeling, and genomic services. Projects are custom-designed with clients and delivered with detailed reports and data packages. Revenue generated through project-based contracts with pharmaceutical, biotech, and nutraceutical companies.

invivobiosystems.com
2Gene Editing Services
TypeOne Time License
Description

CRISPR-based gene editing services for zebrafish and C. elegans models including knock-in, knockout, and transgenic services. Offered as full build, candidate lines, or custom injection mix packages. Revenue from one-time project fees.

invivobiosystems.com
3NIH SBIR Grants
TypeLicensing Royalties
Description

Non-dilutive funding from NIH Small Business Innovation Research grants supporting development of AI-powered technologies like FishCam Smart Rack for zebrafish health monitoring.

einpresswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details8 tiers
1Full Build - Complete gene editing service from design to validated strain delivery
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

$3,812 and up for C. elegans CRISPR Knock-in Full Build; timeline of 8 weeks and up

invivobiosystems.com
2Candidate Lines - Injections and screening,客户提供筛选后的品系
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

$2,679 and up for C. elegans CRISPR Knock-in Candidate Lines; timeline of 6 weeks and up

invivobiosystems.com
3Custom Injection Mix -客户提供分子组分自行注射
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$1,914 and up for C. elegans CRISPR Knock-in Custom Injection Mix; timeline of 4 weeks and up

invivobiosystems.com
4Locus Sequencing and Genotyping
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$935 and up; 2-4 weeks delivery; includes custom genotyping assay and final report

invivobiosystems.com
5Outcrossing Package
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,810 and up; 6-8 weeks delivery; includes outcross strain, custom genotyping assay, and final report

invivobiosystems.com
6Whole-genome Sequencing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,183 and up; 8-10 weeks delivery; includes raw sequencing data and final report

invivobiosystems.com
7Inject Express - Fast CRISPR injection service
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Starts at $440/set; 1 week delivery; one set = 10 injected worms

invivobiosystems.com
8Custom Injection Mix - Full service design and preparation
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Starts at $1,155; 2 weeks and up; includes all molecular components for desired genetic edit

invivobiosystems.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1RapidGen™ Platform
Description

AI-powered platform that generates scalable, decision-ready data from whole-organism models (zebrafish and C. elegans) for therapeutic discovery.

invivobiosystems.com
+3 more records
Core offering1 text field

InVivo Biosystems operates as a contract research organization providing preclinical drug discovery and genome editing services using CRISPR-edited zebrafish and C. elegans whole-organism models. The company delivers fee-for-service compound efficacy testing, toxicity testing, disease modeling, and gene editing (knock-in, knockout, transgenic) for pharmaceutical, biotech, nutraceutical, and academic clients, supported by the proprietary RapidGen™ AI-powered platform and MIC-Drop™ multiplexed CRISPR technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 79% treatment correlation to traditional PDX therapeutic outcomes
+3 more records
Product overview1 text field

InVivo Biosystems operates as a technology and services platform focused on therapeutic discovery using whole-organism models (zebrafish and C. elegans). The core offering is the RapidGen Platform, an AI-powered in vivo discovery system that generates scalable data from conserved biology models. Supporting this platform are specialized technology offerings including MIC-Drop for multiplexed CRISPR gene editing and the ZTX Oncology Platform for cancer drug testing. The company provides comprehensive service offerings across gene editing (CRISPR knockout/knock-in, MosSCI, Tol2 transgenesis), disease modeling (epilepsy, Parkinson's, Alzheimer's, cancer, ocular diseases), preclinical compound testing (toxicity, efficacy, vitality studies), and genomic services (strain validation, maintenance, injection services). The portfolio is unified through the RapidGen Platform which integrates AI-driven data analysis with whole-organism phenotyping capabilities.

Product and service1 record
1RapidGen Platform
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCore Technology PartnerTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-03
Description

Granted InVivo Biosystems an exclusive license for the MIC-Drop CRISPR technology. This licensing agreement provides InVivo with proprietary rights to their multiplexed gene editing platform.

Strategic tierPlatform PartnerTypeTechnology or Integration
Description

Strategic partnership for the ZTX® Oncology Platform, combining BioReperia's tumor xenograft capabilities with InVivo Biosystems' zebrafish platform for accelerated cancer drug discovery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty CRO focused on zebrafish-based preclinical drug discovery and toxicity assessment; directly competes with InVivo Biosystems for pharma/biotech zebrafish toxicology and efficacy screening contracts.

TypeDirect peer
Description

Preclinical CRO offering in vivo oncology and translational research services including zebrafish xenograft platforms (via the ZTX-like capabilities); directly comparable to InVivo's ZTX Oncology Platform offerings.

TypeBroad incumbent
Description

Largest global preclinical CRO offering discovery, safety assessment, and manufacturing services across multiple model organisms; broad incumbent that competes for early-discovery and toxicology spend that InVivo targets.

TypeBroad incumbent
Description

Global CRO/CDMO with deep preclinical discovery services including in vivo pharmacology and disease modeling; competes for outsourced preclinical budgets across pharma/biotech.

TypeBroad incumbent
Description

Preclinical CRO and research models provider with rodent-centric discovery and safety assessment services; competes for the same pharma R&D budgets that InVivo addresses via alternative model organisms.

TypeBroad incumbent
Description

Large-scale preclinical and clinical CRO spun out of Labcorp; competes for outsourced early-discovery and toxicology work with full GLP infrastructure that InVivo currently lacks.

TypeBroad incumbent
Description

Global CRO/CDMO with extensive preclinical discovery and safety assessment capacity; serves large pharma with integrated discovery-to-manufacturing workflows competing for outsourced preclinical studies.

TypeEmerging player
Description

Preclinical CRO specializing in CNS/neuro disease modeling and behavioral phenotyping; overlaps with InVivo's neurotoxicity and neurodegenerative disease model services (Alzheimer's, Parkinson's, epilepsy).

TypeEmerging player
Description

Preclinical services provider with focus on biologics manufacturing and related discovery support; partial overlap with InVivo's preclinical testing workflows for biotech clients.

TypeOthers
Description

Predecessor entity acquired by InVivo Biosystems in 2017 for C. elegans transgenesis capabilities; historically a comparable niche model-organism service provider before integration.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InVivo Biosystems

Preclinical Contract Research Servicesinvivobiosystems.com

InVivo Biosystems is an Eugene, Oregon-based contract research organization providing CRISPR gene editing and preclinical research services using zebrafish and C. elegans whole-organism models for pharmaceutical, biotech, academic, and nutraceutical clients.

What InVivo Biosystems does

InVivo Biosystems is a privately held contract research organization (CRO) founded in 2011 and headquartered in Eugene, Oregon, that provides genome editing and preclinical research services using whole-organism models—primarily zebrafish and C. elegans. The company targets pharmaceutical and biotechnology companies, academic research institutions, and nutraceutical firms, positioning its services as faster, more cost-effective alternatives to traditional rodent-based preclinical workflows. Since inception, InVivo Biosystems has served 400+ clients, delivered 600+ studies, and produced 3,000+ C. elegans transgenic lines, with stated outcomes of 79% treatment correlation to traditional PDX oncology benchmarks and up to 98% reduction in validation study timelines.

The company's core offering is the RapidGen™ Platform, an AI-augmented in vivo discovery system that integrates conserved biology models, advanced genetics, multi-omics readouts, and computer-vision-based behavioral phenotyping to produce decision-ready data packages. Proprietary technologies include MIC-Drop™ (a multiplexed CRISPR platform exclusively licensed from the University of Utah, enabling simultaneous gene editing in F0 generation with non-linear labor scaling), the ZTX® Oncology Platform (zebrafish tumor xenograft for cancer drug efficacy testing, co-developed with BioReperia), and the FishCam Smart Rack (an AI-powered continuous zebrafish colony monitoring system funded through NIH SBIR grants). The intellectual property portfolio includes 10+ issued patents covering gene editing methods, whole-organism phenotyping, and automation.

InVivo Biosystems operates a fee-for-service revenue model with project-based contracts covering CRISPR gene editing (knock-in, knockout, transgenic services), preclinical compound efficacy and toxicity testing, disease modeling across neurological and metabolic indications, and genomic services including strain validation and storage. Pricing is unit-based, with gene editing projects ranging from $440 (Inject Express) to $3,812+ (Full Build CRISPR knock-in), with 50/50 milestone payment structures. The company pursues a consultative, partnership-driven sales motion targeting enterprise clients through direct engagement. Cumulative funding across equity rounds and grants totals approximately $12.8 million, including a $3M seed round led by Rogue Venture Partners in January 2024 and $2.8M in NIH grant funding, supplemented by Phase II SBIR support for FishCam development.

InVivo Biosystems firmographics

Firmographics
Name
InVivo Biosystems
Legal name
InVivo Biosystems
Website
https://invivobiosystems.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
InVivo Biosystems is an Eugene, Oregon-based contract research organization providing CRISPR gene editing and preclinical research services using zebrafish and C. elegans whole-organism models for pharmaceutical, biotech, academic, and nutraceutical clients.
Ownership category
akta.pro rank

InVivo Biosystems industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Preclinical research services
  • CRISPR gene editing
  • Zebrafish disease models
  • Contract research organization
  • In vivo drug discovery

Where InVivo Biosystems is headquartered

Location

Headquarters

HQ city
Eugene
HQ country
United States
HQ region
North America

Offices1 record

Markets served

InVivo Biosystems business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services (CRO): Fee-for-service preclinical research services including compound efficacy testing, toxicity testing, disease modeling, and genomic services. Projects are custom-designed with clients and delivered with detailed reports and data packages. Revenue generated through project-based contracts with pharmaceutical, biotech, and nutraceutical companies.
  2. Gene Editing Services: CRISPR-based gene editing services for zebrafish and C. elegans models including knock-in, knockout, and transgenic services. Offered as full build, candidate lines, or custom injection mix packages. Revenue from one-time project fees.
  3. NIH SBIR Grants: Non-dilutive funding from NIH Small Business Innovation Research grants supporting development of AI-powered technologies like FishCam Smart Rack for zebrafish health monitoring.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractFull Build - Complete gene editing service from design to validated strain delivery
One time/ perpetual licenseMulti-year contractCandidate Lines - Injections and screening,客户提供筛选后的品系
One time/ perpetual licensePay-as-you-goCustom Injection Mix -客户提供分子组分自行注射
Unit PricingPay-as-you-goLocus Sequencing and Genotyping
Unit PricingPay-as-you-goOutcrossing Package
Unit PricingPay-as-you-goWhole-genome Sequencing
Unit PricingPay-as-you-goInject Express - Fast CRISPR injection service
Unit PricingPay-as-you-goCustom Injection Mix - Full service design and preparation

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

InVivo Biosystems product offering

Product offering

Core offering

InVivo Biosystems operates as a contract research organization providing preclinical drug discovery and genome editing services using CRISPR-edited zebrafish and C. elegans whole-organism models. The company delivers fee-for-service compound efficacy testing, toxicity testing, disease modeling, and gene editing (knock-in, knockout, transgenic) for pharmaceutical, biotech, nutraceutical, and academic clients, supported by the proprietary RapidGen™ AI-powered platform and MIC-Drop™ multiplexed CRISPR technology.

Product overview

InVivo Biosystems operates as a technology and services platform focused on therapeutic discovery using whole-organism models (zebrafish and C. elegans). The core offering is the RapidGen Platform, an AI-powered in vivo discovery system that generates scalable data from conserved biology models. Supporting this platform are specialized technology offerings including MIC-Drop for multiplexed CRISPR gene editing and the ZTX Oncology Platform for cancer drug testing. The company provides comprehensive service offerings across gene editing (CRISPR knockout/knock-in, MosSCI, Tol2 transgenesis), disease modeling (epilepsy, Parkinson's, Alzheimer's, cancer, ocular diseases), preclinical compound testing (toxicity, efficacy, vitality studies), and genomic services (strain validation, maintenance, injection services). The portfolio is unified through the RapidGen Platform which integrates AI-driven data analysis with whole-organism phenotyping capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • RapidGen™ Platform: AI-powered platform that generates scalable, decision-ready data from whole-organism models (zebrafish and C. elegans) for therapeutic discovery.
  • MIC-Drop™
  • ZTX® Oncology Platform
  • FishCam Smart Rack

Products and services

  • RapidGen Platform

Quantifiable outcome

  • 79% treatment correlation to traditional PDX therapeutic outcomes
  • +3 more outcomes

Companies that use InVivo Biosystems

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

InVivo Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature4 records

InVivo Biosystems partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core technology partner and platform partner.

  • University of Utahcore technology partnerOEM/ Whitelabel/ Licensing Partner · 3 January 2024Granted InVivo Biosystems an exclusive license for the MIC-Drop CRISPR technology. This licensing agreement provides InVivo with proprietary rights to their multiplexed gene editing platform.
  • BioReperiaplatform partnerTechnology or IntegrationStrategic partnership for the ZTX® Oncology Platform, combining BioReperia's tumor xenograft capabilities with InVivo Biosystems' zebrafish platform for accelerated cancer drug discovery.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

InVivo Biosystems competitors and assessment

Company assessment

Direct peers

  • ZeClinics: Specialty CRO focused on zebrafish-based preclinical drug discovery and toxicity assessment; directly competes with InVivo Biosystems for pharma/biotech zebrafish toxicology and efficacy screening contracts.
  • Crown Bioscience: Preclinical CRO offering in vivo oncology and translational research services including zebrafish xenograft platforms (via the ZTX-like capabilities); directly comparable to InVivo's ZTX Oncology Platform offerings.

Broad incumbents

  • Charles River Laboratories: Largest global preclinical CRO offering discovery, safety assessment, and manufacturing services across multiple model organisms; broad incumbent that competes for early-discovery and toxicology spend that InVivo targets.
  • Evotec: Global CRO/CDMO with deep preclinical discovery services including in vivo pharmacology and disease modeling; competes for outsourced preclinical budgets across pharma/biotech.
  • Inotiv: Preclinical CRO and research models provider with rodent-centric discovery and safety assessment services; competes for the same pharma R&D budgets that InVivo addresses via alternative model organisms.
  • Fortrea (former Labcorp Drug Development/Covance): Large-scale preclinical and clinical CRO spun out of Labcorp; competes for outsourced early-discovery and toxicology work with full GLP infrastructure that InVivo currently lacks.
  • Wuxi AppTec: Global CRO/CDMO with extensive preclinical discovery and safety assessment capacity; serves large pharma with integrated discovery-to-manufacturing workflows competing for outsourced preclinical studies.

Emerging players

  • PsychoGenics: Preclinical CRO specializing in CNS/neuro disease modeling and behavioral phenotyping; overlaps with InVivo's neurotoxicity and neurodegenerative disease model services (Alzheimer's, Parkinson's, epilepsy).
  • Bionova Scientific: Preclinical services provider with focus on biologics manufacturing and related discovery support; partial overlap with InVivo's preclinical testing workflows for biotech clients.

Others

  • Knudra Transgenics: Predecessor entity acquired by InVivo Biosystems in 2017 for C. elegans transgenesis capabilities; historically a comparable niche model-organism service provider before integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

InVivo Biosystems social profiles

Digital presence

InVivo Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InVivo Biosystems leadership team

Management profile

Number of profiles

Profiles4 records

InVivo Biosystems funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InVivo Biosystems M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InVivo Biosystems

What does InVivo Biosystems do?

InVivo Biosystems operates as a contract research organization providing preclinical drug discovery and genome editing services using CRISPR-edited zebrafish and C. elegans whole-organism models. The company delivers fee-for-service compound efficacy testing, toxicity testing, disease modeling, and gene editing (knock-in, knockout, transgenic) for pharmaceutical, biotech, nutraceutical, and academic clients, supported by the proprietary RapidGen™ AI-powered platform and MIC-Drop™ multiplexed CRISPR technology.

Is InVivo Biosystems a public or private company?

InVivo Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was InVivo Biosystems founded?

InVivo Biosystems was founded in 2011. It employs 11 to 50 people.

Where is InVivo Biosystems based?

InVivo Biosystems is headquartered in Eugene, United States, in the North America region.

How does InVivo Biosystems make money?

Three revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are gene Editing Services and NIH SBIR Grants.

Who are InVivo Biosystems's main competitors?

Direct peers on record are ZeClinics and Crown Bioscience. Broad incumbents are Charles River Laboratories, Evotec, Inotiv, Fortrea (former Labcorp Drug Development/Covance) and Wuxi AppTec. Emerging players are PsychoGenics and Bionova Scientific. Knudra Transgenics is listed as an others.

Does InVivo Biosystems have an API?

No public API is recorded for InVivo Biosystems.

What industry is InVivo Biosystems in?

InVivo Biosystems's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireInVivo Biosystems Advances AI Technology for Real Time Animal Health MonitoringInVivo Biosystems announced that it received Phase II SBIR funding from the NIH to develop and commercialize its FishCam AI-powered animal health monitoring system. The system offers continuous, non-invasive monitoring of zebrafish in research facilities, providing integrated health data and enhancing animal welfare.BioPharmaTrendInVivo Biosystems Raises $3M for CRISPR Research and Welcomes New Board ChairmanInVivo Biosystems secured a $3 million investment led by Rogue Venture Partners to accelerate CRISPR technology commercialization and appointed Dr. C. Palani Palaniappan as Chairman of its Board of Directors. The company is leveraging this capital and leadership expertise to advance drug discovery efforts through its proprietary genome-edited animal models. This development coincides with broader industry recognition of CRISPR's transformative potential in therapeutic outcomes.PrwebInVivo Biosystems Secures New Investment to Accelerate CRISPR InnovationInVivo Biosystems secured $3 million in new investment led by Rogue Venture Partners, with participation from Portland Seed Fund, ONAMI, and Launch Oregon, to accelerate CRISPR-edited animal research for drug discovery. The company also appointed C. Palani Palaniappan, Ph.D., as Chairman of its Board of Directors effective December 8, 2023.InvivobiosystemsInVivo Biosystems Secures New InvestmentInVivo Biosystems secured $3 million in new investment led by Rogue Venture Partners to further its CRISPR-edited animal models for drug discovery. The company also appointed C. Palani Palaniappan as Chairman of the Board and highlighted recent milestones including a $2.8M NIH grant and an exclusive license from the University of Utah.PrwebNemaMetrix Expands Business to Capitalize on In-vivo Solutions to Help Speed Testing for Critical Disease Therapeutics / Changes Operating Name to InVivo BiosystemsNemaMetrix is changing its operating name to InVivo Biosystems and expanding its research platforms to accelerate in-vivo insights for critical disease therapeutics. The company now offers CRISPR-powered genome editing solutions using C. elegans and zebrafish to speed drug development, with applications for COVID-19 research. It aims to help address rare diseases, which are estimated to reach $169B by 2022.